Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in pediatric solid tumors and lymphoma
NL-OMON59069Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in melanoma, Nonhematologic neoplasms, lymphoma and 2 more, sponsored by Merck & Co. Primary endpoints: Objective response rate by RECIST 1.1 per site assessment, Objective response rate for MSI-H or TMB-H solid tumors by RECIST 1.1 per site assessment and 4 more. Started Sep 2023; status: completed.
02
Drugs
03
Conditions
melanomaNonhematologic neoplasmslymphomaclassical Hodgkin lymphoma (cHL)microsatellite instability-high cancer
Beyond the preview
Go deeper on NL-OMON59069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59069.